4.15 USD
-0.32 (-7.16%)
4.41 USD
+0.26 (+6.27%)
Overall ARTV gets a fundamental rating of 3 out of 10. We evaluated ARTV against 525 industry peers in the Biotechnology industry. While ARTV has a great health rating, there are worries on its profitability. ARTV is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- ARTV had negative earnings in the past year.
- ARTV had a negative operating cash flow in the past year.
1.2 Ratios
- The Return On Assets of ARTV (-53.20%) is comparable to the rest of the industry.
- With a decent Return On Equity value of -61.28%, ARTV is doing good in the industry, outperforming 60.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.2% | ||
| ROE | -61.28% | ||
| ROIC | N/A |
ROA(3y)-34.23%
ROA(5y)N/A
ROE(3y)-55.15%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ARTV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ARTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
- ARTV has more shares outstanding than it did 1 year ago.
- The debt/assets ratio for ARTV is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -0.52, we must say that ARTV is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of ARTV (-0.52) is comparable to the rest of the industry.
- ARTV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.52 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
- ARTV has a Current Ratio of 11.65. This indicates that ARTV is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 11.65, ARTV belongs to the top of the industry, outperforming 86.48% of the companies in the same industry.
- A Quick Ratio of 11.65 indicates that ARTV has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 11.65, ARTV belongs to the top of the industry, outperforming 86.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.65 | ||
| Quick Ratio | 11.65 |
3. Growth
3.1 Past
- ARTV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.09%.
- Looking at the last year, ARTV shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
- The Revenue for ARTV have been decreasing by -49.95% on average. This is quite bad
EPS 1Y (TTM)7.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.86%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-49.95%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- ARTV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.25% yearly.
- ARTV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 189.66% yearly.
EPS Next Y35.88%
EPS Next 2Y17.05%
EPS Next 3Y17.4%
EPS Next 5Y8.25%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y189.66%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- ARTV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARTV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ARTV's earnings are expected to grow with 17.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.05%
EPS Next 3Y17.4%
5. Dividend
5.1 Amount
- No dividends for ARTV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ARTIVA BIOTHERAPEUTICS INC / ARTV FAQ
What is the ChartMill fundamental rating of ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ARTV.
Can you provide the valuation status for ARTIVA BIOTHERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to ARTIVA BIOTHERAPEUTICS INC (ARTV). This can be considered as Overvalued.
What is the profitability of ARTV stock?
ARTIVA BIOTHERAPEUTICS INC (ARTV) has a profitability rating of 1 / 10.
How financially healthy is ARTIVA BIOTHERAPEUTICS INC?
The financial health rating of ARTIVA BIOTHERAPEUTICS INC (ARTV) is 7 / 10.